Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

160 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials.
Michot JM, Benajiba L, Faivre L, Baldini C, Haddag L, Bonnet C, Massard C, Bigot F, Bigenwald C, Verret B, Thomas ZAP, Varga A, Gazzah A, Hollebecque A, Ghez D, Lazarovici J, Balheda R, Jeanson A, Postel-Vinay S, Danu A, Soria JC, Paoletti X, Ribrag V. Michot JM, et al. Among authors: paoletti x. Invest New Drugs. 2018 Feb;36(1):62-74. doi: 10.1007/s10637-017-0480-x. Epub 2017 Jun 9. Invest New Drugs. 2018. PMID: 28597151 Clinical Trial.
Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors.
Geoerger B, Hargrave D, Thomas F, Ndiaye A, Frappaz D, Andreiuolo F, Varlet P, Aerts I, Riccardi R, Jaspan T, Chatelut E, Le Deley MC, Paoletti X, Saint-Rose C, Leblond P, Morland B, Gentet JC, Méresse V, Vassal G; ITCC (Innovative Therapies for Children with Cancer) European Consortium. Geoerger B, et al. Among authors: paoletti x. Neuro Oncol. 2011 Jan;13(1):109-18. doi: 10.1093/neuonc/noq141. Epub 2010 Oct 25. Neuro Oncol. 2011. PMID: 20974795 Free PMC article. Clinical Trial.
[Dose finding methods for targeted agents: new perspectives].
Paoletti X, Postel-Vinay S, Servois V, Doussau A, Ollivier L, Le Tourneau C. Paoletti X, et al. Bull Cancer. 2010 Dec;97(12):1485-95. doi: 10.1684/bdc.2010.1232. Bull Cancer. 2010. PMID: 21220226 Free article. Review. French.
Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study.
Postel-Vinay S, Collette L, Paoletti X, Rizzo E, Massard C, Olmos D, Fowst C, Levy B, Mancini P, Lacombe D, Ivy P, Seymour L, Le Tourneau C, Siu LL, Kaye SB, Verweij J, Soria JC. Postel-Vinay S, et al. Among authors: paoletti x. Eur J Cancer. 2014 Aug;50(12):2040-9. doi: 10.1016/j.ejca.2014.04.031. Epub 2014 May 28. Eur J Cancer. 2014. PMID: 24880774
Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials.
Moreno L, Rubie H, Varo A, Le Deley MC, Amoroso L, Chevance A, Garaventa A, Gambart M, Bautista F, Valteau-Couanet D, Geoerger B, Vassal G, Paoletti X, Pearson AD. Moreno L, et al. Among authors: paoletti x. Pediatr Blood Cancer. 2017 Jan;64(1):25-31. doi: 10.1002/pbc.26192. Epub 2016 Aug 24. Pediatr Blood Cancer. 2017. PMID: 27555472
Patient-reported tolerability of adverse events in phase 1 trials.
Henon C, Lissa D, Paoletti X, Thibault C, Le Tourneau C, Lanoy E, Hollebecque A, Massard C, Soria JC, Postel-Vinay S. Henon C, et al. Among authors: paoletti x. ESMO Open. 2017 Jun 23;2(2):e000148. doi: 10.1136/esmoopen-2016-000148. eCollection 2017. ESMO Open. 2017. PMID: 28761740 Free PMC article.
160 results